Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 13 | 2011 | 79 | 2.190 |
Why?
|
| Breast Neoplasms | 13 | 2010 | 1533 | 1.170 |
Why?
|
| Histiocytosis, Sinus | 2 | 2012 | 5 | 0.740 |
Why?
|
| Radiation Injuries | 5 | 2015 | 97 | 0.700 |
Why?
|
| Brain Neoplasms | 10 | 2014 | 371 | 0.600 |
Why?
|
| Thoracic Wall | 2 | 2008 | 20 | 0.570 |
Why?
|
| Catheterization | 2 | 2009 | 209 | 0.550 |
Why?
|
| Skin Diseases | 2 | 2010 | 122 | 0.520 |
Why?
|
| Radiotherapy | 4 | 2017 | 86 | 0.500 |
Why?
|
| Mastectomy, Segmental | 7 | 2010 | 63 | 0.500 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2010 | 32 | 0.480 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2010 | 61 | 0.470 |
Why?
|
| Tomography, Spiral Computed | 2 | 2010 | 57 | 0.410 |
Why?
|
| Optic Nerve Diseases | 1 | 2011 | 31 | 0.390 |
Why?
|
| Spinal Cord Compression | 1 | 2011 | 23 | 0.390 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 29 | 0.390 |
Why?
|
| Ribs | 2 | 2008 | 25 | 0.390 |
Why?
|
| Uterine Neoplasms | 2 | 2008 | 99 | 0.380 |
Why?
|
| Iridium Radioisotopes | 4 | 2008 | 11 | 0.370 |
Why?
|
| Radiodermatitis | 3 | 2007 | 8 | 0.370 |
Why?
|
| Glioma | 3 | 2009 | 140 | 0.370 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 92 | 0.370 |
Why?
|
| Tumor Burden | 2 | 2014 | 132 | 0.360 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2010 | 37 | 0.360 |
Why?
|
| Middle Aged | 28 | 2017 | 21119 | 0.360 |
Why?
|
| Dacarbazine | 2 | 2010 | 32 | 0.350 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2010 | 57 | 0.350 |
Why?
|
| Lymphatic Irradiation | 1 | 2009 | 3 | 0.340 |
Why?
|
| Radiation Dosage | 5 | 2014 | 419 | 0.330 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 34 | 0.330 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2009 | 30 | 0.330 |
Why?
|
| Seroma | 1 | 2008 | 3 | 0.330 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2008 | 6 | 0.330 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2008 | 9 | 0.330 |
Why?
|
| Orbital Diseases | 1 | 2008 | 21 | 0.320 |
Why?
|
| Eisenmenger Complex | 1 | 2008 | 4 | 0.320 |
Why?
|
| Splenomegaly | 1 | 2008 | 13 | 0.310 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 329 | 0.310 |
Why?
|
| Rib Fractures | 1 | 2008 | 37 | 0.310 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2007 | 8 | 0.310 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 14 | 0.310 |
Why?
|
| Aged, 80 and over | 13 | 2011 | 4843 | 0.310 |
Why?
|
| Graft Rejection | 2 | 2009 | 458 | 0.310 |
Why?
|
| Radiosurgery | 4 | 2014 | 66 | 0.300 |
Why?
|
| Humans | 52 | 2017 | 68549 | 0.290 |
Why?
|
| Palliative Care | 2 | 2008 | 271 | 0.290 |
Why?
|
| Female | 35 | 2017 | 38021 | 0.290 |
Why?
|
| Dose-Response Relationship, Radiation | 5 | 2009 | 84 | 0.280 |
Why?
|
| Meningeal Neoplasms | 2 | 2017 | 42 | 0.270 |
Why?
|
| Meningioma | 2 | 2017 | 54 | 0.270 |
Why?
|
| Adult | 25 | 2012 | 21379 | 0.260 |
Why?
|
| Heart Transplantation | 1 | 2009 | 328 | 0.260 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 378 | 0.260 |
Why?
|
| Combined Modality Therapy | 7 | 2010 | 951 | 0.250 |
Why?
|
| Pain | 1 | 2008 | 472 | 0.240 |
Why?
|
| Aged | 18 | 2011 | 14842 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2016 | 2222 | 0.230 |
Why?
|
| Radiotherapy Dosage | 9 | 2011 | 125 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2010 | 444 | 0.220 |
Why?
|
| Gadolinium DTPA | 2 | 2016 | 48 | 0.210 |
Why?
|
| Sarcoidosis | 1 | 2002 | 77 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 125 | 0.180 |
Why?
|
| Follow-Up Studies | 9 | 2008 | 3256 | 0.180 |
Why?
|
| Glioblastoma | 2 | 2015 | 219 | 0.180 |
Why?
|
| Quality of Life | 2 | 2008 | 1515 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2016 | 7268 | 0.170 |
Why?
|
| Contrast Media | 2 | 2016 | 595 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 349 | 0.160 |
Why?
|
| Virus Activation | 1 | 2017 | 15 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2017 | 23 | 0.150 |
Why?
|
| Cerebellar Nuclei | 1 | 2016 | 11 | 0.140 |
Why?
|
| Particle Accelerators | 2 | 1995 | 10 | 0.140 |
Why?
|
| Skin Neoplasms | 2 | 2000 | 375 | 0.140 |
Why?
|
| Radiotherapy, Conformal | 2 | 2008 | 24 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2017 | 7028 | 0.140 |
Why?
|
| Male | 19 | 2017 | 37283 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 248 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2017 | 3703 | 0.130 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.130 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.130 |
Why?
|
| Melanoma | 1 | 1996 | 335 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2012 | 40 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2010 | 82 | 0.100 |
Why?
|
| Spinal Puncture | 1 | 2011 | 38 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2010 | 164 | 0.100 |
Why?
|
| Prednisone | 1 | 2011 | 104 | 0.100 |
Why?
|
| Uterine Perforation | 1 | 2011 | 3 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2010 | 714 | 0.100 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2010 | 5 | 0.100 |
Why?
|
| Neuropil | 1 | 2010 | 6 | 0.100 |
Why?
|
| Ganglioglioma | 1 | 2010 | 11 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 536 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2008 | 2324 | 0.090 |
Why?
|
| Young Adult | 3 | 2012 | 5710 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2010 | 24 | 0.090 |
Why?
|
| Uterus | 1 | 2011 | 77 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2011 | 150 | 0.090 |
Why?
|
| Radioimmunotherapy | 1 | 2010 | 4 | 0.090 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2010 | 6 | 0.090 |
Why?
|
| Pseudolymphoma | 1 | 2010 | 6 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 129 | 0.090 |
Why?
|
| Leukemia, Myeloid | 1 | 2010 | 39 | 0.090 |
Why?
|
| Wilms Tumor | 1 | 2010 | 47 | 0.090 |
Why?
|
| Time Factors | 5 | 2010 | 4655 | 0.090 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 119 | 0.090 |
Why?
|
| Adolescent | 7 | 2010 | 8904 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 119 | 0.090 |
Why?
|
| Pericardium | 1 | 2010 | 97 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2011 | 222 | 0.090 |
Why?
|
| Consensus | 1 | 2010 | 211 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 206 | 0.080 |
Why?
|
| Whole-Body Irradiation | 1 | 2009 | 52 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2008 | 64 | 0.080 |
Why?
|
| Cholecystitis, Acute | 1 | 2008 | 4 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 285 | 0.080 |
Why?
|
| Multiple Organ Failure | 1 | 2008 | 36 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2010 | 245 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2008 | 94 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 1994 | 778 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2010 | 276 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2008 | 88 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 511 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2015 | 2356 | 0.070 |
Why?
|
| Spleen | 1 | 2008 | 301 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 467 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 168 | 0.070 |
Why?
|
| Multi-Institutional Systems | 1 | 2006 | 3 | 0.070 |
Why?
|
| Neoplasms | 1 | 2017 | 1664 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 333 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2002 | 624 | 0.070 |
Why?
|
| Relative Biological Effectiveness | 1 | 2005 | 10 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 20 | 0.060 |
Why?
|
| Carcinoma in Situ | 1 | 2005 | 45 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 852 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2005 | 36 | 0.060 |
Why?
|
| Fanconi Anemia | 1 | 2004 | 7 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2004 | 21 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2010 | 274 | 0.060 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2002 | 8 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2002 | 27 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2002 | 74 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2002 | 16 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 2004 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 514 | 0.050 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2000 | 5 | 0.050 |
Why?
|
| Osteolysis, Essential | 1 | 2000 | 6 | 0.050 |
Why?
|
| Nail Diseases | 1 | 2000 | 13 | 0.050 |
Why?
|
| Foot Diseases | 1 | 2000 | 20 | 0.050 |
Why?
|
| Toes | 1 | 2000 | 27 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2798 | 0.050 |
Why?
|
| Neurocytoma | 1 | 1999 | 3 | 0.040 |
Why?
|
| Algorithms | 2 | 2014 | 1195 | 0.040 |
Why?
|
| Anus Neoplasms | 2 | 1993 | 13 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 15 | 0.040 |
Why?
|
| Pleural Neoplasms | 1 | 1998 | 7 | 0.040 |
Why?
|
| Pulmonary Blastoma | 1 | 1998 | 7 | 0.040 |
Why?
|
| Varicellovirus | 1 | 2017 | 1 | 0.040 |
Why?
|
| Herpesvirus 2, Human | 1 | 2017 | 10 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2017 | 46 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 198 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2017 | 30 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 47 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 561 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 839 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 1996 | 30 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 1996 | 95 | 0.040 |
Why?
|
| Survival Rate | 2 | 2017 | 1055 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2010 | 1040 | 0.040 |
Why?
|
| DNA Repair | 1 | 1996 | 127 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2016 | 78 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 110 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1851 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 330 | 0.030 |
Why?
|
| Risk Factors | 1 | 2005 | 5720 | 0.030 |
Why?
|
| Skull Neoplasms | 1 | 1994 | 23 | 0.030 |
Why?
|
| Prognosis | 3 | 2015 | 2093 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1996 | 848 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1994 | 311 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.030 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1991 | 15 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 621 | 0.030 |
Why?
|
| Dysgerminoma | 2 | 1988 | 9 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Radiation Oncology | 1 | 2010 | 12 | 0.020 |
Why?
|
| Axilla | 1 | 2010 | 36 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2083 | 0.020 |
Why?
|
| Melphalan | 1 | 2010 | 15 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 413 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 64 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 59 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 91 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 216 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 98 | 0.020 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1989 | 29 | 0.020 |
Why?
|
| Child | 3 | 2016 | 6401 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 1172 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2010 | 239 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1641 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2010 | 3187 | 0.020 |
Why?
|
| Pinealoma | 1 | 1988 | 2 | 0.020 |
Why?
|
| Age Factors | 2 | 2010 | 1860 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 791 | 0.020 |
Why?
|
| Enteritis | 1 | 1987 | 6 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1987 | 27 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 5300 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 1989 | 267 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1046 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 191 | 0.020 |
Why?
|
| Arizona | 1 | 2006 | 9 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 2689 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 737 | 0.020 |
Why?
|
| Mammography | 1 | 2007 | 310 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2005 | 223 | 0.010 |
Why?
|
| Brain | 1 | 2014 | 2176 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 365 | 0.010 |
Why?
|
| South Carolina | 2 | 1998 | 2752 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 20880 | 0.010 |
Why?
|
| Infant | 2 | 1998 | 2891 | 0.010 |
Why?
|
| Pregnancy | 1 | 2002 | 2334 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 1140 | 0.010 |
Why?
|
| Craniotomy | 1 | 1994 | 33 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1993 | 169 | 0.010 |
Why?
|
| Models, Structural | 1 | 1991 | 22 | 0.010 |
Why?
|
| Ependymoma | 1 | 1991 | 13 | 0.010 |
Why?
|
| Neuroma, Acoustic | 1 | 1991 | 17 | 0.010 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1991 | 57 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1991 | 151 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1990 | 186 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1989 | 47 | 0.010 |
Why?
|
| Laparotomy | 1 | 1989 | 65 | 0.010 |
Why?
|
| Choriocarcinoma | 1 | 1987 | 7 | 0.000 |
Why?
|
| Teratoma | 1 | 1987 | 22 | 0.000 |
Why?
|
| Reoperation | 1 | 1989 | 467 | 0.000 |
Why?
|
| Intestines | 1 | 1987 | 114 | 0.000 |
Why?
|
| Biopsy | 1 | 1988 | 539 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1988 | 799 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1990 | 2455 | 0.000 |
Why?
|
| Methods | 1 | 1982 | 156 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1990 | 1070 | 0.000 |
Why?
|